← back to search

Richard Aspinall

Portsmouth Hospitals NHS Trust · GB
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Liver Diseases and Immunity, and Hepatitis C virus research.
h-index
28
citations
3,477
works
125
NIH funding
primary concept
Medicine
email

Recent publications

Implementation of a care bundle improves PBC management
JHEP Reports 2025cited by 0position: middledoi
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
Hepatology 2023cited by 109position: middledoi
Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Alimentary Pharmacology & Therapeutics 2023cited by 34position: middledoi
Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery
JHEP Reports 2023cited by 24position: middledoi
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Journal of Hepatology 2022cited by 78position: middledoi
New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK
The Lancet 2021cited by 41position: middledoi
Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK
The Lancet 2019cited by 78position: middledoi
Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK
The Lancet 2018cited by 64position: middledoi
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials
Clinical Infectious Diseases 2016cited by 91position: middledoi
The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin‐α
Liver International 2016cited by 51position: middledoi
New metrics for the Lancet Standing Commission on Liver Disease in the UK
The Lancet 2016cited by 42position: middledoi
Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis
The Lancet 2014cited by 600position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Palak Trivedi · University of Amsterdam3 papers (2023–2025)Charles A. McWherter · CymaBay Therapeutics (United States)2 papers (2022–2023)Laith Alrubaiy · University of London2 papers (2023–2025)Nadir Abbas · National Health Service2 papers (2023–2025)Stuart C. Gordon · Northwestern Medicine2 papers (2022–2023)Paul J. Thuluvath · University of Utah2 papers (2022–2023)Cynthia Levy · University of Miami2 papers (2022–2023)Graham R. Foster · Queen Mary University of London2 papers (2014–2016)Joanna Leithead · University of Birmingham2 papers (2023–2025)Yvonne Dörffel · Charité - Universitätsmedizin Berlin2 papers (2022–2023)Andreas E. Kremer · University of Zurich2 papers (2022–2023)Mark G. Swain · Newcastle University2 papers (2022–2023)David Sheridan · University of Edinburgh2 papers (2022–2023)Rebecca Jones · Imperial College London2 papers (2023–2025)Stephen A. Harrison · Oxford Centre for Diabetes, Endocrinology and Metabolism2 papers (2022–2023)Yun‐Jung Choi · Jeonju National University of Education2 papers (2022–2023)David Jones · Newcastle upon Tyne Hospital2 papers (2023–2023)Guy Neff · NIHR Birmingham Biomedical Research Centre2 papers (2022–2023)Michael Galambos · Emory Healthcare2 papers (2022–2023) · 2 papers (2014–2016)